As of 2024-07-27, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (5.85) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.44 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -506.0%.
The range of the Relative Valuation is (5.10) - (5.85) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 24.8x - 31.8x | 31.3x |
| Forward P/E multiples | 20.2x - 28.5x | 25.6x |
| Fair Price | (5.10) - (5.85) | (5.85) |
| Upside | -453.9% - -506.4% | -506.0% |
| Date | P/E |
| 2024-07-26 | -7.01 |
| 2024-07-25 | -7.20 |
| 2024-07-24 | -7.15 |
| 2024-07-23 | -7.10 |
| 2024-07-22 | -6.72 |
| 2024-07-19 | -6.57 |
| 2024-07-18 | -6.62 |
| 2024-07-17 | -6.86 |
| 2024-07-16 | -6.91 |
| 2024-07-15 | -6.37 |
| 2024-07-12 | -6.13 |
| 2024-07-11 | -6.18 |
| 2024-07-10 | -5.26 |
| 2024-07-09 | -4.76 |
| 2024-07-08 | -4.61 |
| 2024-07-05 | -4.55 |
| 2024-07-03 | -4.61 |
| 2024-07-02 | -4.67 |
| 2024-07-01 | -4.84 |
| 2024-06-28 | -4.96 |
| 2024-06-27 | -4.81 |
| 2024-06-26 | -4.50 |
| 2024-06-25 | -4.17 |
| 2024-06-24 | -4.40 |
| 2024-06-21 | -4.43 |
| 2024-06-20 | -4.57 |
| 2024-06-18 | -4.92 |
| 2024-06-17 | -5.11 |
| 2024-06-14 | -5.21 |
| 2024-06-13 | -5.45 |
| 2024-06-12 | -5.65 |
| 2024-06-11 | -5.40 |
| 2024-06-10 | -5.30 |
| 2024-06-07 | -5.16 |
| 2024-06-06 | -5.21 |
| 2024-06-05 | -5.35 |
| 2024-06-04 | -5.50 |
| 2024-06-03 | -5.55 |
| 2024-05-31 | -5.45 |
| 2024-05-30 | -5.26 |
| 2024-05-29 | -5.01 |
| 2024-05-28 | -5.21 |
| 2024-05-24 | -5.35 |
| 2024-05-23 | -5.30 |
| 2024-05-22 | -5.35 |
| 2024-05-21 | -5.50 |
| 2024-05-20 | -5.60 |
| 2024-05-17 | -5.60 |
| 2024-05-16 | -5.55 |
| 2024-05-15 | -5.74 |